Results 1 to 10 of about 22,145 (200)

Combinatorial therapy with resveratrol sensitizes glioblastoma to NKG2D CAR-T cells [PDF]

Frontiers in Immunology
Chimeric antigen receptor T-cell (CAR-T) therapies have shown potential in clinical trials for glioblastoma, yet treatment responses vary due to heterogeneous antigen expression and post-treatment immune escape.
Wei Liang, Wei Liang, Yexiao Tang, Muhammad Auwal Saliu, Muhammad Auwal Saliu, Mansur Dabai Salisu, Mansur Dabai Salisu, Cuimei Chen, Zhiming Xu, Shu Xu, Maoxuan Liu, Maoxuan Liu, Xiaochun Wan, Xiaochun Wan   +13 more
doaj   +2 more sources

Interaction between NKG2D and its ligands MICA/B activates the DAP12/SYK/p53/p21 axis to drive pulmonary fibrosis [PDF]

Frontiers in Immunology
BackgroundPulmonary fibrosis (PF) is a progressive, fatal interstitial lung disease with limited therapeutic options. Emerging evidence implicates immune–fibrotic crosstalk in PF pathogenesis, although the underlying molecular mechanisms remain poorly ...
Caiping Zhao, Caiping Zhao, Hong Ren, Qingming Ke, Qiuzhu Chen, Qiuzhu Chen, Jinlian He, Ruimin Tian, Hudan Pan, Hudan Pan, Liang Liu, Liang Liu, Liang Liu   +12 more
doaj   +2 more sources

Expression of NKG2D Receptors in CD3+ and CD56+ Cells in Blood Samples of Pre-eclampsia Patients and the Effect of Silymarin on Their Activity in Vitro [PDF]

مجله دانشکده پزشکی اصفهان, 2022
Background: Increased NK cells or their cytokine activity in endometrium and peripheral blood of mothers with pre-eclampsia have been reported. NKG2D is a cell surface receptor that can be used to detect NK cell and lymphocytic activity. Plant flavonoids
Ali Reza Andalib, Nafiseh Esmaeil, Elahe Zarean, Golzar Ahmadi, Fahimeh Hosseininasab, Mohadeseh Toghyani   +5 more
doaj   +1 more source

CAR T-Cell Therapy with NKG2D Chimeric Antigen Receptor in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Клиническая онкогематология, 2021
NK-cells as innate immunity elements manifest key reactions of antitumor immune response. NKG2D is an activating transmembrane receptor of NK-cells which is responsible for cytotoxicity initiation in response to the binding of specific ligands of ...
Kseniya Aleksandrovna Levchuk, E. V. Belotserkovskaya, D. Yu. Pozdnyakov, L. L. Girshova, A. Yu. Zaritskey, A. V. Petukhov   +5 more
doaj   +1 more source

Recent Advances in Molecular Mechanisms of the NKG2D Pathway in Hepatocellular Carcinoma

Biomolecules, 2020
Hepatocellular carcinoma is a common malignant tumor with high mortality. Its malignant proliferation, invasion, and metastasis are closely related to the cellular immune function of the patients.
Jian Wang, Cun-Di Li, Lin Sun
doaj   +1 more source

Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity

Frontiers in Immunology, 2021
The activating immune receptor natural killer group member D (NKG2D) and its cognate ligands represent a fundamental surveillance system of cellular distress, damage or transformation.
Eric Alves, Eric Alves, Emily McLeish, Pilar Blancafort, Pilar Blancafort, Pilar Blancafort, Jerome D. Coudert, Jerome D. Coudert, Jerome D. Coudert, Silvana Gaudieri, Silvana Gaudieri, Silvana Gaudieri   +11 more
doaj   +1 more source

CEBPA mutants down-regulate AML cell susceptibility to NK-mediated lysis by disruption of the expression of NKG2D ligands, which can be restored by LSD1 inhibition

OncoImmunology, 2022
NK group 2, member D (NKG2D) is one of the most critical activating receptors expressed by natural killer (NK) cells. There is growing evidence that acute myeloid leukemia (AML) cells may evade NK cell-mediated cell lysis by expressing low or no ligands ...
Meng Liu, Mengbao Du, Jian Yu, Zijun Qian, Yang Gao, Wenjue Pan, Xiujie Zhao, Mowang Wang, Huimin Li, Jiaqi Zheng, Qianshuo Huang, Li-Mengmeng Wang, Haowen Xiao   +12 more
doaj   +1 more source

Regulation and gene expression profiling of NKG2D positive human cytomegalovirus-primed CD4+ T-cells. [PDF]

PLoS ONE, 2012
NKG2D is a stimulatory receptor expressed by natural killer (NK) cells, CD8(+) T-cells, and γδ T-cells. NKG2D expression is normally absent from CD4(+) T-cells, however recently a subset of NKG2D(+) CD4(+) T-cells has been found, which is specific for ...
Helle Jensen, Lasse Folkersen, Søren Skov   +2 more
doaj   +1 more source

Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway

Oncogenesis, 2021
Pancreatic carcinoma (PC) is one of the most common malignancies. Chimeric antigen receptor (CAR)-modified T cells has achieved remarkable efficacy in the treatment of hematological malignancies.
Yaoxin Gao, Haizhen Lin, Dandan Guo, Sijia Cheng, Ying Zhou, Li Zhang, Jie Yao, Muhammad Asad Farooq, Iqra Ajmal, Yixin Duan, Cong He, Lei Tao, Shijia Wu, Mingyao Liu, Wenzheng Jiang   +14 more
doaj   +1 more source

DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

OncoImmunology, 2019
Chimeric antigen receptor (CAR) T cell immunotherapies have shown remarkable efficacy in treating multiple types of hematological malignancies but are not sufficiently effective at treating solid tumors. NKG2D is a strong activating receptor for NK cells
Ruocong Zhao, Lin Cheng, Zhiwu Jiang, Xinru Wei, Baiheng Li, Qiting Wu, Suna Wang, Simiao Lin, Youguo Long, Xuchao Zhang, Yilong Wu, Xin Du, Duanqing Pei, Pentao Liu, Yangqiu Li, Shuzhong Cui, Yao Yao, Peng Li   +17 more
doaj   +1 more source